Amid Mylan launching an EpiPen generic alternative, the “Fast Money Halftime Report” traders and CNBC’s Jim Cramer share their take on Mylan and the biotech sector.
Stocks closed lower, with health care shedding 1.5 percent, while investors eagerly awaited a speech from Janet Yellen.
The “Fast Money” traders debate top trades including Netflix, Bristol-Meyers and more.
Shares of Bristol-Myers Squibb briefly fell more than 17 percent in opening trade Friday after its cancer drug failed to meet targets in a late-stage study.
$21 billion is how much investors wiped off the firm after its trial to broaden the use of one of its most promising drugs failed.
Biotech stocks this week hit their highest levels since January. And some analysts say the stocks have room to run.
Shares of Bristol-Myers Squibb drop on a failed drug trial. Damien Conover, Morningstar equity analyst, discusses his views on the future Bristol-Myers.
Shares of Bristol Myers Squibb are way down today while shares of Merck are up. Here's why, and what's next, with Tony Butler, Guggenheim Securities.
While Bristol Myers Squibb is having its worst day in nearly 16 years, shares of Merck is up 5 percent year over year. Nancy Tengler, Heartland Financial, discusses one of her largest holdings.
Bristol Myers Squibb is having its worst day in nearly 16 years after failing to meet goals for a lung cancer drug. Alex Arfaei, BMO, discusses.
CNBC's Meg Tirrell reports why Bristol-Myers shares are dropping while Merck shares are soaring. The “Fast Money Halftime Report” traders; Stephanie Link, TIAA Global Asset Management; and John Spallanzani, GFI Group chief macro strategist, discuss their views on buying Bristol-Myers on the dip.
Jim Cramer said that he was shocked after Bristol-Myers Squibb announced its lung cancer drug failed in a late-stage study.
The pharmaceutical company reported its cancer drug failed to reach its goals for treating advanced non-small cell lung cancer.
Shares of Merck soared in premarket trading Friday, after the failure of a drug from rival Bristol-Myers Squibb in a late stage study.
Jim Cramer crunched the numbers on two stocks notorious for short-sellers to determine if they are portfolio worthy.
CNBC's Meg Tirrell reports the latest of what Pfizer CEO Ian Read has to say on biotech valuations, the election and more. The “Fast Money Halftime Report” traders and Stephanie Link, TIAA Global Asset Management, weigh in.
The "Fast Money" traders share their first moves for the market open.
The "Fast Money" traders share their final trades of the day, including J.C. Penney, Biogen and more.
Biogen and Ionis Pharmaceuticals soar on a new muscle-disorder drug for babies, CNBC's Meg Tirrell reports. The "Fast Money Halftime Report" traders weigh in.
"Fast Money Halftime Report" traders Jon Najarian and Pete Najarian discuss unusual activity with FireEye and Abbott.